Osteopontin deficiency dampens the pro-atherogenic effect of uraemia

Cardiovascular Research

Volumn 98, Issue 3, 2013, Pages 352-359

  Pedersen, Tanja X ^a,b   Madsen, Marie ^b   Junker, Nanna ^b   Christoffersen, Christina ^a   Vikeså, Jonas ^a   Bro, Susanne ^a   Hultgårdh Nilsson, Anna ^c   Nielsen, Lars Bo ^a,b  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

5 6 Nephrectomy; Atherosclerosis; Mouse; Osteopontin; Uraemia

Indexed keywords

OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTERY WALL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; HEMATOPOIETIC CELL; MACROPHAGE; MOUSE; NEPHRECTOMY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UREMIA;

5/6 NEPHRECTOMY; ATHEROSCLEROSIS; MOUSE; OSTEOPONTIN; URAEMIA;

ANIMALS; AORTA, THORACIC; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL DEDIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENOTYPE; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEPHRECTOMY; OSTEOPONTIN; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; UREMIA;

EID: 84877942003     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt049     Document Type: Article

References (46)

1. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495.
2. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004;15(Suppl. 1):S77-S80.
3. Bro S, Moeller F, Andersen CB, Olgaard K, Nielsen LB. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J Am Soc Nephrol 2004;15:1495-1503.
4. Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003;14:311-316.
5. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005;16:109-116.
6. Bro S, Borup R, Andersen CB, Moeller F, Olgaard K, Nielsen LB. Uremia-specific effects in the arterial media during development of uremic atherosclerosis in apolipo-protein E-deficient mice. Arterioscler Thromb Vasc Biol 2006;26:570-575.
7. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009;11: 206-213.
8. O'Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994;14:1648-1656.
9. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal 2009;3:311-322.
10. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopon-tin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686-1696.
11. Maziere C, Gomila C, Maziere JC. Oxidized low-density lipoprotein increases osteo-pontin expression by generation of oxidative stress. Free Radic Biol Med 2010;48: 1382-1387.
12. King JY, Ferrara R, Tabibiazar R, Spin JM, Chen MM, Kuchinsky A et al. Pathway analysis of coronary atherosclerosis. Physiol Genomics 2005;23:103-118.
13. Ailawadi G, Moehle CW, Pei H, Walton SP, Yang Z, Kron IL et al. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg 2009;138:1392-1399.
14. Mack CP. Signaling mechanisms that regulate smooth muscle cell differentiation. Arter-ioscler Thromb Vasc Biol 2011;31:1495-1505.
15. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 2010;11:353-365.
16. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994;74:214-224.
17. Yue TL, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, Johanson K et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res 1994;214:459-464.
18. Wiedon A, Tolle M, Bastine J, Schuchardt M, Huang T, Jankowski V et al. Uridine ad-enosine tetraphosphate (Up4A) is a strong inductor of smooth muscle cell migration via activation of the P2Y2 receptor and cross-communication to the PDGF receptor. Biochem Biophys Res Commun 2012;417:1035-1040.
19. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008;19:333-345.
20. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27: 2302-2309.
21. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M. Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev 2010;18:125-131.
22. Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, Inobe M et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 2002;16:111-117.
23. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterios-cler Thromb Vasc Biol 2003;23:1029-1034.
24. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M et al. Osteopon-tin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002;91:77-82.
25. Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F. Osteopontin trans-genic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 2003;107:679-681.
26. Strom A, Franzen A, Wangnerud C, Knutsson AK, Heinegard D, Hultgardh-Nilsson A. Altered vascular remodeling in osteopontin-deficient atherosclerotic mice. J Vasc Res 2004;41:314-322.
27. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S et al. Angio-tensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003;112:1318-1331.
28. Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A et al. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron Clin Pract 2011;117:c363-c372.
29. Lorenzen J, Kramer R, Kliem V, Bode-Boeger SM, Veldink H, Haller H et al. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest 2010;40: 294-300.
30. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724-1731.
31. Franzen A, Hultenby K, Reinholt FP, Onnerfjord P, Heinegard D. Altered osteoclast development and function in osteopontin deficient mice. J Orthop Res 2008;26: 721-728.
32. Pedersen TX, Bro S, Andersen MH, Etzerodt M, Jauhiainen M, Moestrup S et al. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice. Atherosclerosis 2009;202:372-381.
33. Bro S, Bollano E, Bruel A, Olgaard K, Nielsen LB. Cardiac structure and function in a mouse model of uraemia without hypertension. Scand J Clin Lab Invest 2008;68: 660-666.
34. Davis-Dusenbery BN, Wu C, Hata A. Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol 2011;31: 2370-2377.
35. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 2012;95:156-164.
36. Lattanzio MR, Weir MR. Does blockade of the renin-angiotensin-aldosterone system slow progression of all forms of kidney disease? Curr Hypertens Rep 2010; 12:369-377.
37. Bro S, Binder CJ, Witztum JL, Olgaard K, Nielsen LB. Inhibition of the reninangiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:1080-1086.
38. Shimizu S, Okuda N, Kato N, Rittling SR, Okawa A, Shinomiya K et al. Osteopontin deficiency impairs wear debris-induced osteolysis via regulation of cytokine secretion from murine macrophages. Arthritis Rheum 2010;62:1329-1337.
39. Zheng W, Li R, Pan H, He D, Xu R, Guo TB et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 2009;60:1957-1965.
40. Hu WY, Fukuda N, Ikeda Y, Suzuki R, Tahira Y, Takagi H et al. Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype. J Cell Physiol 2003;196:284-292.
41. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overex-pression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993;13:120-125.
42. Hultgardh-Nilsson A, Lovdahl C, Blomgren K, Kallin B, Thyberg J. Expression of phenotypeand proliferation-related genes in rat aortic smooth muscle cells in primary culture. Cardiovasc Res 1997;34:418-430.
43. Chaulet H, Desgranges C, Renault MA, Dupuch F, Ezan G, Peiretti F et al. Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin. Circ Res 2001;89:772-778.
44. Ortiz A, Massy ZA, Fliser D, Lindholm B, Wiecek A, Martinez-Castelao A et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol 2012;8:141-150.
45. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:333-337.
46. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008; 1:43-49.